Kardigan Inc. Nasdaq Debut and IPO Details
Kardigan Inc., a heart‑health focused biotechnology company, completed its initial public offering on the Nasdaq Global Market under the ticker KARD on Thursday, raising $400 million. The company sold 25 million shares at the set IPO price of $16 per share. Earlier filings indicated that the firm had marketed 23.3 million shares within a price range of $14 to $16.
The shares opened at $16.25 at 12:39 p.m. New York time, immediately trading above the IPO price, and climbed over 27% within the first hour, reaching above $20.30 by approximately 1:30 p.m. This price action gave Kardigan a market capitalization of nearly $1.8 billion based on its outstanding share count.
Executive Background and Strategic Outlook
Chief Executive Officer Tassos Gianakakos previously led MyoKardia, which was acquired by Bristol‑Myers Squibb Co. for roughly $13 billion in 2020. Gianakakos stated that the expanding market for GLP‑1 weight‑loss drugs will not diminish the demand for innovative cardiovascular therapies. Kardigan is developing separate drug candidates targeting genetic dilated cardiomyopathy, calcific aortic valve stenosis, and acute severe hypertension.
Financial Performance
For the first quarter of 2026, Kardigan reported a net loss of $56.1 million, a widening from the $18 million loss recorded in the same quarter of the prior year. The company’s financial position was previously bolstered in October by a $254 million Series B financing round, led by new investors Fidelity Management & Research Co. and T. Rowe Price Investment Management Inc., alongside existing shareholders ARCH Venture Partners and HRTG Partners. ARCH and HRTG each hold 22.4% of Kardigan’s equity.
Underwriters and Lead Managers
The IPO was underwritten and managed by a syndicate comprising JPMorgan Chase & Co., Jefferies Financial Group Inc., Leerink Partners, and Toronto‑Dominion Bank.
Market Context
Cardiovascular disease remains the leading cause of death in the United States, with rising prevalence of high blood pressure, diabetes, and obesity contributing to heightened risk, according to the American Heart Association.